Evan B. Garden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Evan B. Garden has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Alexander C. Small
Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine; Montefiore at 1250 Waters Place, Bronx, NY 10461
3 shared publications - Michael A. Palese
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
3 shared publications - Ettore Vulcano
Columbia University Division of Orthopedics at Mount Sinai Medical Center, Miami Beach, USA
2 shared publications - Jashvant Poeran
Hospital for Special Surgery, New York, New York
2 shared publications - Jesse Chan
Department of Computational Applied Mathematics and Operations Research Rice University
2 shared publications - Jimmy J. Chan
Icahn School of Medicine at Mount Sinai, New York, NY, USA
2 shared publications
Latest Publications
- 23 January 2025
- Published by Wiley in BJU International
- Vol. 136 (2) , 321-328
Immunotherapy‐based neoadjuvant treatment and complication rates after radical cystectomy
Objective: To assess 30‐ and 90‐day postoperative complication rates in patients who underwent robot‐assisted radical cystectomy (RARC) after receiving novel immunotherapy‐based neoadjuvant treatment. Methods: A bi‐centre analysis was conducted in patients who underwent RARC with intracorporeal urinary diversion and who received an immunotherapy‐based neoadjuvant regimen between 2017 and 2023. Complications were classified using the Clavien–Dindo system. Results: The cohort included 136 patients, with a median (interquartile range [IQR]) age of 66 (61–73) years, of whom 22 were female (16.2%). The overall 30‐day and 31–90‐day Clavien–Dindo grade ≥3a complication rates were 15.4%, and 14.7%, respectively. The most common cumulative 90‐day complications by category were infectious (59.6%), genitourinary (33.1%), and gastrointestinal (22.7%). The median (IQR) hospital stay was 11 (7–16) days, and 36 patients (26.5%) required readmission. Eighty‐four patients received monotherapy with an immune checkpoint inhibitor and 52 received combination immunochemotherapy. A higher rate of 30‐day infectious complications was seen in the immuno‐monotherapy group (46.4% vs 26.9%; P = 0.03), while pulmonary complications were more commonly reported in the combination immunochemotherapy group (9.6% vs 1.2%; P = 0.03). No statistically significant differences were found in the other complication categories between the groups. Eleven patients (8.1%) experienced 13 (9.6%) immune‐related adverse events (irAEs). The most common irAEs were hypothyroidism and dermatitis. Conclusions: The cumulative 90‐day complication rate after novel immunotherapy‐based neoadjuvant treatment appears higher than those previously reported for RARC alone or for chemotherapy‐based neoadjuvant regimens. We observed irAEs in 8.1% of patients after RARC, highlighting the need for urologists to recognise such events.
- 23 January 2025
- Published by Wiley in BJU International
- Vol. 136 (2) , 321-328
Immunotherapy‐based neoadjuvant treatment and complication rates after radical cystectomy
Objective: To assess 30‐ and 90‐day postoperative complication rates in patients who underwent robot‐assisted radical cystectomy (RARC) after receiving novel immunotherapy‐based neoadjuvant treatment. Methods: A bi‐centre analysis was conducted in patients who underwent RARC with intracorporeal urinary diversion and who received an immunotherapy‐based neoadjuvant regimen between 2017 and 2023. Complications were classified using the Clavien–Dindo system. Results: The cohort included 136 patients, with a median (interquartile range [IQR]) age of 66 (61–73) years, of whom 22 were female (16.2%). The overall 30‐day and 31–90‐day Clavien–Dindo grade ≥3a complication rates were 15.4%, and 14.7%, respectively. The most common cumulative 90‐day complications by category were infectious (59.6%), genitourinary (33.1%), and gastrointestinal (22.7%). The median (IQR) hospital stay was 11 (7–16) days, and 36 patients (26.5%) required readmission. Eighty‐four patients received monotherapy with an immune checkpoint inhibitor and 52 received combination immunochemotherapy. A higher rate of 30‐day infectious complications was seen in the immuno‐monotherapy group (46.4% vs 26.9%; P = 0.03), while pulmonary complications were more commonly reported in the combination immunochemotherapy group (9.6% vs 1.2%; P = 0.03). No statistically significant differences were found in the other complication categories between the groups. Eleven patients (8.1%) experienced 13 (9.6%) immune‐related adverse events (irAEs). The most common irAEs were hypothyroidism and dermatitis. Conclusions: The cumulative 90‐day complication rate after novel immunotherapy‐based neoadjuvant treatment appears higher than those previously reported for RARC alone or for chemotherapy‐based neoadjuvant regimens. We observed irAEs in 8.1% of patients after RARC, highlighting the need for urologists to recognise such events.
- 30 September 2022
- Published by Elsevier in Revue de Chirurgie Orthopédique et Traumatologique
- Vol. 108 (7) , 855
Impact économique des comorbidités dans l’arthroplastie totale de cheville et l’arthrodèse de cheville
- 30 September 2022
- Published by Elsevier in Revue de Chirurgie Orthopédique et Traumatologique
- Vol. 108 (7) , 855
Impact économique des comorbidités dans l’arthroplastie totale de cheville et l’arthrodèse de cheville
- 1 January 2022
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 9 (1) , 25-31
A Comparison of Pharmaceutical Prices for Generic Erectile Dysfunction and Benign Prostatic Hyperplasia Medication in 2 Socioeconomically Disparate New York City Neighborhoods
Purpose:Erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) are frequently managed with medications. Variability and poor understanding of medication prices have been shown to ...
- 1 January 2022
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 9 (1) , 25-31
A Comparison of Pharmaceutical Prices for Generic Erectile Dysfunction and Benign Prostatic Hyperplasia Medication in 2 Socioeconomically Disparate New York City Neighborhoods
Purpose:Erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) are frequently managed with medications. Variability and poor understanding of medication prices have been shown to ...
- 26 November 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 223 (6) , 1120-1125
Adrenalectomy outcomes predicted by a 5-item frailty index (5-iFI) in the ACS-NSQIP database
- 26 November 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 223 (6) , 1120-1125
Adrenalectomy outcomes predicted by a 5-item frailty index (5-iFI) in the ACS-NSQIP database
- 4 September 2021
- Published by Springer Nature in Journal of Anesthesia
- Vol. 35 (6) , 879-888
Peripheral nerve block use in ankle arthroplasty and ankle arthrodesis: utilization patterns and impact on outcomes
Purpose Ankle arthrodesis and total ankle arthroplasty (TAA) are often associated with significant postoperative pain. While this may be mitigated by the use of peripheral nerve blocks (PNB), large-scale data are lacking. Using national data, we aimed to evaluate PNB utilization pattern and its impact on outcomes. Methods This retrospective cohort study utilized data from the nationwide database (2006–2016) on TAA (n = 5,290) and ankle arthrodesis (n = 14,709) procedures. PNB use was defined from billing; outcomes included opioid utilization, length and cost of stay, discharge to a skilled nurse facility, and opioid-related complications. Mixed-effects models estimated the association between PNB use and outcomes, separate by procedure type and inpatient/outpatient setting. We report odds ratios and 95% confidence intervals (CI). Results Overall, PNB was utilized in 8.7% of TAA and 9.9% of ankle arthrodesis procedures, with increased utilization from 2006 to 2016 of 2.6% to 11.3% and 5.2% to 12.0%, respectively. After adjustment for relevant covariates, PNB use was significantly associated with decreased total opioid utilization specifically in the inpatient setting in TAA ( − 16.9% CI − 23.9%; − 9.1%) and ankle arthrodesis procedures ( − 18.9% CI − 24.4; − 13.0%), this was particularly driven by a decrease in opioid utilization on the day of surgery. No clinically relevant effects were observed for other outcomes. Conclusion PNB utilization is associated with substantial reductions in opioid utilization, particularly in the inpatient setting. Our study is in support of a wider use of this analgesic technique, which may translate into more benefits in terms of clinical outcomes and resource utilization. Level of Evidence III.
- 4 September 2021
- Published by Springer Nature in Journal of Anesthesia
- Vol. 35 (6) , 879-888
Peripheral nerve block use in ankle arthroplasty and ankle arthrodesis: utilization patterns and impact on outcomes
Purpose Ankle arthrodesis and total ankle arthroplasty (TAA) are often associated with significant postoperative pain. While this may be mitigated by the use of peripheral nerve blocks (PNB), large-scale data are lacking. Using national data, we aimed to evaluate PNB utilization pattern and its impact on outcomes. Methods This retrospective cohort study utilized data from the nationwide database (2006–2016) on TAA (n = 5,290) and ankle arthrodesis (n = 14,709) procedures. PNB use was defined from billing; outcomes included opioid utilization, length and cost of stay, discharge to a skilled nurse facility, and opioid-related complications. Mixed-effects models estimated the association between PNB use and outcomes, separate by procedure type and inpatient/outpatient setting. We report odds ratios and 95% confidence intervals (CI). Results Overall, PNB was utilized in 8.7% of TAA and 9.9% of ankle arthrodesis procedures, with increased utilization from 2006 to 2016 of 2.6% to 11.3% and 5.2% to 12.0%, respectively. After adjustment for relevant covariates, PNB use was significantly associated with decreased total opioid utilization specifically in the inpatient setting in TAA ( − 16.9% CI − 23.9%; − 9.1%) and ankle arthrodesis procedures ( − 18.9% CI − 24.4; − 13.0%), this was particularly driven by a decrease in opioid utilization on the day of surgery. No clinically relevant effects were observed for other outcomes. Conclusion PNB utilization is associated with substantial reductions in opioid utilization, particularly in the inpatient setting. Our study is in support of a wider use of this analgesic technique, which may translate into more benefits in terms of clinical outcomes and resource utilization. Level of Evidence III.
- 1 July 2021
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 8 (4) , 466-471
Disposable versus Reusable Cystoscopes: A Micro-Costing Value Analysis in High-Volume and Low-Volume Urology Practices
Introduction:Disposable single-use cystoscopes have become increasingly available, demonstrating comparable quality to reusable cystoscopes while eliminating the need for reprocessing and r...
- 1 July 2021
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 8 (4) , 466-471
Disposable versus Reusable Cystoscopes: A Micro-Costing Value Analysis in High-Volume and Low-Volume Urology Practices
Introduction:Disposable single-use cystoscopes have become increasingly available, demonstrating comparable quality to reusable cystoscopes while eliminating the need for reprocessing and r...
- Open Access
- 4 May 2021
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 96 (8) , 1156-1159
Key Insights From the Development and Implementation of a Novel Virtual Interview Process for Medical School Admissions During the COVID-19 Pandemic
Problem: During the COVID-19 pandemic, medical schools have offered a virtual application process. Minimal literature is available to guide best practices. Approach: The Icahn School of Medicine at Mount Sinai (ISMMS) implemented a completely virtual interview (VI) process in April/May 2020. Large-group sessions for applicants, interviews with applicants, and ISMMS Admissions Committee meetings occurred via Zoom (Zoom Video Communications, Inc., San Jose, California). Large-group sessions and committee meetings occurred via communal conference calls, while one-on-one, semistructured interviews occurred in individual breakout rooms. ISMMS offered live, virtual question-and-answer sessions with students and faculty, plus digital resources describing program features. After the interview day, applicants and interviewers were invited to complete anonymous surveys regarding their experiences with and perspectives of VI. Outcomes: Of 125 applicants and 20 interviewers, 99 (79%) and 18 (90%), respectively, completed at least part of the survey. Of the applicants, 85/95 (89%) agreed VI met or exceeded expectations, with many praising the day’s organization and convenience, and 71/95 (75%) agreed they received a sufficient sense of the student body. A minority (n = 39/95 [41%]) felt limited in their ability to learn about the institution (commonly related to their inability to tour campus), and a majority (n =74/91 [81%]) would have preferred an in-person interview. Most interviewers felt comfortable assessing applicants’ verbal communication skills (n = 13/16 [81%]), and most (n = 12/17 [71%]) felt VI should be an option for future applicants. Next Steps: VI, likely to be a temporary-but-universal fixture of upcoming application cycles, may benefit applicants and interviewers alike by saving resources and diversifying those involved. Next steps are developing programming that will permit applicants to virtually explore the institution and connect more with current students. Future research should evaluate potential bias in VI to ensure an equitable application process for all.
- 4 May 2021
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 96 (8) , 1156-1159
Open AccessKey Insights From the Development and Implementation of a Novel Virtual Interview Process for Medical School Admissions During the COVID-19 Pandemic
Problem: During the COVID-19 pandemic, medical schools have offered a virtual application process. Minimal literature is available to guide best practices. Approach: The Icahn School of Medicine at Mount Sinai (ISMMS) implemented a completely virtual interview (VI) process in April/May 2020. Large-group sessions for applicants, interviews with applicants, and ISMMS Admissions Committee meetings occurred via Zoom (Zoom Video Communications, Inc., San Jose, California). Large-group sessions and committee meetings occurred via communal conference calls, while one-on-one, semistructured interviews occurred in individual breakout rooms. ISMMS offered live, virtual question-and-answer sessions with students and faculty, plus digital resources describing program features. After the interview day, applicants and interviewers were invited to complete anonymous surveys regarding their experiences with and perspectives of VI. Outcomes: Of 125 applicants and 20 interviewers, 99 (79%) and 18 (90%), respectively, completed at least part of the survey. Of the applicants, 85/95 (89%) agreed VI met or exceeded expectations, with many praising the day’s organization and convenience, and 71/95 (75%) agreed they received a sufficient sense of the student body. A minority (n = 39/95 [41%]) felt limited in their ability to learn about the institution (commonly related to their inability to tour campus), and a majority (n =74/91 [81%]) would have preferred an in-person interview. Most interviewers felt comfortable assessing applicants’ verbal communication skills (n = 13/16 [81%]), and most (n = 12/17 [71%]) felt VI should be an option for future applicants. Next Steps: VI, likely to be a temporary-but-universal fixture of upcoming application cycles, may benefit applicants and interviewers alike by saving resources and diversifying those involved. Next steps are developing programming that will permit applicants to virtually explore the institution and connect more with current students. Future research should evaluate potential bias in VI to ensure an equitable application process for all.